Lakefront Biotherapeutics
GLPGF
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.11B
Close$
Share Statistics
| Market cap | $2.11 Billion |
|---|---|
| Enterprise Value | $2.05 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $4.87 |
| Beta | 0.11 |
| Outstanding Shares | 70,033,000 |
Return
| Return on Equity | 18.34% |
|---|---|
| Return on Assets | 17.69% |
| Return on Invested Capital | 18.04% |
Valuation & Multiples
| P/E Ratio | 3.56 |
|---|---|
| PEG | -3.49 |
| Price to Sales | 2.28 |
| Price to Book Ratio | 0.69 |
| Enterprise Value to Revenue | 2.07 |
| Enterprise Value to EBIT | 3.47 |
| Enterprise Value to Net Income | 3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
$6.01 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.81
Average shareholder expectationRevenue Estimate
$7.31 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Galapagos NV
452 employees
CEO: Onno van de Stolpe Galapagos N.V. is a fully-integrated biopharmaceutical firm dedicated to discovering, developing, and bringing to market innovative therapies for conditions where patient needs are largely unaddressed. The company boasts a robust pipelin...